生物制药公司Seres Therapeutics, Inc.近期宣布实施一系列旨在延长企业运营周期的战略调整措施。作为成本优化计划的重要组成部分，该公司决定精简组织架构，将全球员工规模缩减约30%。此次人员调整预计将有效降低运营支出，为核心研发项目争取更充裕的资金支持周期。
生物制药公司Seres Therapeutics, Inc.近期宣布实施一系列旨在延长企业运营周期的战略调整措施。作为成本优化计划的重要组成部分，该公司决定精简组织架构，将全球员工规模缩减约30%。此次人员调整预计将有效降低运营支出，为核心研发项目争取更充裕的资金支持周期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.